Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Relatlimab in MSS Advanced Colorectal Cancer
NCT03642067Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2019
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of relatlimab in colorectal cancer (CRC) (3 cohorts), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Objective Response Rate at 12 months. Started Feb 2019; status: completed.
02
Drugs
relatlimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03642067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642067.